vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and SANFILIPPO JOHN B & SON INC (JBSS). Click either name above to swap in a different company.
SANFILIPPO JOHN B & SON INC is the larger business by last-quarter revenue ($314.8M vs $236.8M, roughly 1.3× CROSS COUNTRY HEALTHCARE INC). SANFILIPPO JOHN B & SON INC runs the higher net margin — 5.7% vs -35.0%, a 40.7% gap on every dollar of revenue. On growth, SANFILIPPO JOHN B & SON INC posted the faster year-over-year revenue change (4.6% vs -23.6%). SANFILIPPO JOHN B & SON INC produced more free cash flow last quarter ($40.0M vs $16.1M). Over the past eight quarters, SANFILIPPO JOHN B & SON INC's revenue compounded faster (7.6% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
John B. Sanfilippo & Son Inc. (JBSS) is a leading US processor, marketer and distributor of high-quality tree nuts, peanuts, dried fruits, and value-added snack products. It serves retail, foodservice, and industrial ingredient customers primarily across North America, offering both branded and private label product lines.
CCRN vs JBSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $314.8M |
| Net Profit | $-82.9M | $18.0M |
| Gross Margin | — | 18.8% |
| Operating Margin | -30.2% | 8.3% |
| Net Margin | -35.0% | 5.7% |
| Revenue YoY | -23.6% | 4.6% |
| Net Profit YoY | -2109.7% | 32.1% |
| EPS (diluted) | $-2.56 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $314.8M | ||
| Q3 25 | $250.1M | $298.7M | ||
| Q2 25 | $274.1M | $269.1M | ||
| Q1 25 | $293.4M | $260.9M | ||
| Q4 24 | $309.9M | $301.1M | ||
| Q3 24 | $315.1M | $276.2M | ||
| Q2 24 | $339.8M | $269.6M | ||
| Q1 24 | $379.2M | $271.9M |
| Q4 25 | $-82.9M | $18.0M | ||
| Q3 25 | $-4.8M | $18.7M | ||
| Q2 25 | $-6.7M | $13.5M | ||
| Q1 25 | $-490.0K | $20.2M | ||
| Q4 24 | $-3.8M | $13.6M | ||
| Q3 24 | $2.6M | $11.7M | ||
| Q2 24 | $-16.1M | $10.0M | ||
| Q1 24 | $2.7M | $13.5M |
| Q4 25 | — | 18.8% | ||
| Q3 25 | 20.4% | 18.1% | ||
| Q2 25 | 20.4% | 18.1% | ||
| Q1 25 | 20.0% | 21.4% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | 20.4% | 16.9% | ||
| Q2 24 | 20.8% | 18.5% | ||
| Q1 24 | 20.4% | 18.1% |
| Q4 25 | -30.2% | 8.3% | ||
| Q3 25 | -2.4% | 9.0% | ||
| Q2 25 | -2.1% | 7.5% | ||
| Q1 25 | -0.3% | 10.8% | ||
| Q4 24 | -1.1% | 6.4% | ||
| Q3 24 | 0.9% | 6.2% | ||
| Q2 24 | -5.7% | 5.4% | ||
| Q1 24 | 0.8% | 6.7% |
| Q4 25 | -35.0% | 5.7% | ||
| Q3 25 | -1.9% | 6.3% | ||
| Q2 25 | -2.4% | 5.0% | ||
| Q1 25 | -0.2% | 7.7% | ||
| Q4 24 | -1.2% | 4.5% | ||
| Q3 24 | 0.8% | 4.2% | ||
| Q2 24 | -4.7% | 3.7% | ||
| Q1 24 | 0.7% | 5.0% |
| Q4 25 | $-2.56 | $1.53 | ||
| Q3 25 | $-0.15 | $1.59 | ||
| Q2 25 | $-0.20 | $1.15 | ||
| Q1 25 | $-0.02 | $1.72 | ||
| Q4 24 | $-0.13 | $1.16 | ||
| Q3 24 | $0.08 | $1.00 | ||
| Q2 24 | $-0.47 | $0.85 | ||
| Q1 24 | $0.08 | $1.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $2.4M |
| Total DebtLower is stronger | — | $28.8M |
| Stockholders' EquityBook value | $322.8M | $370.1M |
| Total Assets | $449.0M | $617.7M |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $2.4M | ||
| Q3 25 | $99.1M | $714.0K | ||
| Q2 25 | $81.2M | $585.0K | ||
| Q1 25 | $80.7M | $1.3M | ||
| Q4 24 | $81.6M | $336.0K | ||
| Q3 24 | $64.0M | $442.0K | ||
| Q2 24 | $69.6M | $484.0K | ||
| Q1 24 | $5.2M | $377.0K |
| Q4 25 | — | $28.8M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $14.6M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | — | $6.0M | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $6.4M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $322.8M | $370.1M | ||
| Q3 25 | $408.1M | $362.8M | ||
| Q2 25 | $412.2M | $360.7M | ||
| Q1 25 | $418.2M | $346.6M | ||
| Q4 24 | $419.0M | $325.6M | ||
| Q3 24 | $424.7M | $310.8M | ||
| Q2 24 | $433.3M | $322.6M | ||
| Q1 24 | $462.4M | $321.8M |
| Q4 25 | $449.0M | $617.7M | ||
| Q3 25 | $538.2M | $598.7M | ||
| Q2 25 | $553.8M | $597.6M | ||
| Q1 25 | $576.2M | $590.0M | ||
| Q4 24 | $589.3M | $545.3M | ||
| Q3 24 | $597.4M | $519.4M | ||
| Q2 24 | $602.9M | $515.6M | ||
| Q1 24 | $648.4M | $491.9M |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $62.5M |
| Free Cash FlowOCF − Capex | $16.1M | $40.0M |
| FCF MarginFCF / Revenue | 6.8% | 12.7% |
| Capex IntensityCapex / Revenue | 0.9% | 7.1% |
| Cash ConversionOCF / Net Profit | — | 3.48× |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $32.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $62.5M | ||
| Q3 25 | $20.1M | $32.1M | ||
| Q2 25 | $4.2M | $36.5M | ||
| Q1 25 | $5.7M | $-25.9M | ||
| Q4 24 | $24.2M | $11.0M | ||
| Q3 24 | $7.5M | $8.9M | ||
| Q2 24 | $82.4M | $35.2M | ||
| Q1 24 | $6.0M | $5.3M |
| Q4 25 | $16.1M | $40.0M | ||
| Q3 25 | $17.9M | $7.3M | ||
| Q2 25 | $2.3M | $23.0M | ||
| Q1 25 | $3.8M | $-37.6M | ||
| Q4 24 | $21.7M | $-2.7M | ||
| Q3 24 | $6.3M | $-3.0M | ||
| Q2 24 | $79.6M | $24.4M | ||
| Q1 24 | $3.8M | $-1.3M |
| Q4 25 | 6.8% | 12.7% | ||
| Q3 25 | 7.2% | 2.4% | ||
| Q2 25 | 0.8% | 8.6% | ||
| Q1 25 | 1.3% | -14.4% | ||
| Q4 24 | 7.0% | -0.9% | ||
| Q3 24 | 2.0% | -1.1% | ||
| Q2 24 | 23.4% | 9.0% | ||
| Q1 24 | 1.0% | -0.5% |
| Q4 25 | 0.9% | 7.1% | ||
| Q3 25 | 0.9% | 8.3% | ||
| Q2 25 | 0.7% | 5.0% | ||
| Q1 25 | 0.6% | 4.5% | ||
| Q4 24 | 0.8% | 4.5% | ||
| Q3 24 | 0.4% | 4.3% | ||
| Q2 24 | 0.8% | 4.0% | ||
| Q1 24 | 0.6% | 2.4% |
| Q4 25 | — | 3.48× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | -1.29× | ||
| Q4 24 | — | 0.81× | ||
| Q3 24 | 2.92× | 0.77× | ||
| Q2 24 | — | 3.52× | ||
| Q1 24 | 2.23× | 0.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
